Light-guided bronchoscopy for advanced lung cancer after chemoradiotherapy
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether a special dye can make cancer cells glow during a bronchoscopy, helping doctors see and biopsy tumors more precisely. It is for people with stage III lung cancer that cannot be removed by surgery and who have already completed chemoradiotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have stage III non-small cell lung cancer that cannot be surgically removed.
- You have completed chemotherapy and radiation therapy together.
- You are eligible to receive maintenance immunotherapy (durvalumab).
- You have a tumor or lymph node that can be reached with a bronchoscopy for biopsy.
- You are well enough to undergo a research bronchoscopy, including possible sedation or general anesthesia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of chemotherapy, radiation, and immunotherapy (durvalumab) for people with stage III non-small cell lung cancer that cannot be removed with surgery. The goal is to see if giving a smaller, more focused radiation dose can be just as effective with fewer side effects.
This trial gives a combination of chemotherapy and durvalumab (an immunotherapy drug) before surgery or radiation, then durvalumab alone afterward. It aims to shrink the tumor and improve outcomes for people with stage III non-small cell lung cancer that is borderline resectable.
This trial tests if giving the immunotherapy drug durvalumab after chemoradiation and surgery helps people with stage 3 non-small cell lung cancer. You will receive standard chemoradiation, then have surgery, and then get durvalumab to see if it lowers the chance of the cancer coming back.
This trial studies whether adding durvalumab (an immune therapy) to standard chemoradiation before surgery can improve outcomes for people with stage III, resectable lung cancer. It aims to help shrink the tumor and improve chances of successful treatment.
This trial studies adding focused radiation to some cancer spots in people with stage III non-small cell lung cancer (NSCLC) whose cancer did not fully stop after standard chemoradiation and durvalumab. The goal is to control a small number of growing spots (or more than a few) and improve outcomes after durvalumab.
This trial tests adding durvalumab (an immunotherapy) after chemotherapy, surgery, and more durvalumab for people with early-stage, operable non-small cell lung cancer. It aims to see if this extra treatment helps prevent the cancer from coming back.
Hear when a new Stage III Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.